Buprenorphine versus Methadone Maintenance for Opioid Dependence
The DOI matches its Crossref record.
Abstract
Buprenorphine at 2 mg and 6 mg daily was compared with methadone at 35 mg and 65 mg during 24 weeks of maintenance among 125 opioid-dependent patients. As hypothesized, 6 mg of buprenorphine were superior to 2 mg of buprenorphine in reducing illicit opioid use, but higher dosage did not improve treatment retention. Self-reported illicit opioid use declined substantially in all groups, but by the third month, significantly more heroin abuse was reported at 2 mg than at 6 mg of buprenorphine or of methadone. From an initial average of $1860/month, month 3 usage dropped to $41 (methadone 65 mg), $73 (methadone 35 mg), $118 (buprenorphine 6 mg), and $351/month (buprenorphine 2 mg). Days of use also dropped from 29 days to 1.7 (methadone 65 mg), 2.8 (methadone 35 mg), 4.0 (buprenorphine 6 mg), and 6.6 days/month (buprenorphine 2 mg). This relatively low efficacy for 2 mg of buprenorphine persisted through month 6 of the trial, with 7.2 days/month and $235/month of use for buprenorphine at 2 mg versus 1.9 days/month and $65/month for the other three groups. Increased opioid abuse also was associated with significantly greater and persistent opioid withdrawal symptoms. Our secondary hypothesis, that buprenorphine would be equivalent to methadone in efficacy, was not supported. Treatment retention was significantly better on methadone (20 vs. 16 weeks), and methadone patients had significantly more opioid-free urines (51% vs. 26%). Abstinence for at least 3 weeks was also more common on methadone than buprenorphine (65% vs. 27%).(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although methadone is superior to buprenorphine in improving addiction outcomes in opioid-dependent patients, buprenorphine has a better safety profile.21–23, 25”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [21]
In the citing paper
“Buprenorphine, a partial μ-opioid receptor agonist and κ-opioid receptor antagonist with a half-life of 2.33 ± 0.24 hours might be an alternative to methadone because it is effective in treating opioid addiction or pain.21–26”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [21]
In the citing paper
“Although methadone is superior to buprenorphine in improving addiction outcomes in opioid-dependent patients, buprenorphine has a better safety profile.21–23, 25”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [21]
Citations
Cites
Still being checked.
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
“, 1999), 5053 participants; ! Buprenorphine maintenance treatments (BMTs) versus MMTs: 11 studies (Fischer et al., 1999; Johnson et al., 1992; Johnson et al., 2000; Kosten et al., 1993; Ling et al., 1996; Mattick, Ali, et al., 2003; Pani, Meremmani, Pirastu, Tagliamonte, & Gessa, 2000; Petitjean et al., 2001; Schotten…”
InfluentialThe neurobiology of opioid dependence: implications for treatment
Kosten, T., & George, T. (2002) · Science & Practice Perspectives · doi:10.1151/spp021113 · Cited by 505
Self-citationBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Metadata
- Authors
- KOSTEN, T. R., SCHOTTENFELD, R., ZIEDONIS, D., & FALCIONI, J.
- Affiliations
- Yale University (US)
- Venue
- The Journal of Nervous and Mental Disease
- Published
- 1993-06
- Volume
- 181
- Issue
- 6
- Pages
- 358-364
- ISSN
- 0022-3018 (ISSN-L)
- OpenAlex
- W2002091306
- Cited by
- 267
- References
- 0
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 3 · 2013: 5 · 2012: 8
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Nervous and Mental Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r18da006190-02, 5p50da004060-13)
- National Institute on Drug Abuse (P50-DA04060, R01DA005626, R18-DA 06190)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, methadone, opioid use disorder, opioid maintenance treatment, heroin use, opioid withdrawal symptoms, treatment retention, opioid abstinence, dose comparison
- MeSH terms
- Adult, Buprenorphine, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Heroin Dependence, Humans, Male, Methadone, Opioid-Related Disorders, Substance Abuse Detection, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine versus Methadone Maintenance for Opioid Dependence. https://app.cochat.ai/papers/10.1097/00005053-199306000-00004
- The paper
- KOSTEN, T. R., SCHOTTENFELD, R., ZIEDONIS, D., & FALCIONI, J. (1993). Buprenorphine versus Methadone Maintenance for Opioid Dependence. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-199306000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.